Hatton M Q, Allen M B, Vathenen S V, Feely M P, Cooke N J
Department of Respiratory Medicine, General Infirmary at Leeds, UK.
Thorax. 1996 Mar;51(3):323-4. doi: 10.1136/thx.51.3.323.
Corticosteroid trials are an important part of the assessment of patients with chronic airways obstruction, but false negative results will occur if the treatment is not taken. To determine compliance low dose phenobarbitone has been used as a marker.
Thirty six patients referred to a chest clinic for assessment of their airways obstruction were studied. They were instructed to take eight capsules (each containing 5 mg prednisolone and 0.5 mg phenobarbitone) per day for two weeks. The response was assessed by home peak flow monitoring and clinic spirometric tests. Plasma phenobarbitone levels were measured after the trial to enable calculation of the dose to plasma concentration ratio (level to dose ratio, LDR) and the result was compared with the reference range for fully compliant individuals.
Five patients defaulted from follow up, 23 had LDR values within the expected range, and eight had low LDR values consistent with poor compliance. The nine patients with steroid responsive disease (> 20% improvement in peak flow or spirometric parameters) all had LDR values in the expected range.
Excluding those who defaulted whose compliance must be questionable, eight (26%) patients did not fully comply with the steroid trial. Not all patients who fail to respond to a two week home steroid trial have a steroid "unresponsive" disease.
皮质类固醇试验是慢性气道阻塞患者评估的重要组成部分,但如果不进行治疗会出现假阴性结果。为确定依从性,低剂量苯巴比妥被用作标志物。
对36名转诊至胸部诊所评估气道阻塞的患者进行研究。他们被要求每天服用8粒胶囊(每粒含5毫克泼尼松龙和0.5毫克苯巴比妥),持续两周。通过家庭峰值流量监测和诊所肺量计测试评估反应。试验结束后测量血浆苯巴比妥水平,以计算剂量与血浆浓度比(水平与剂量比,LDR),并将结果与完全依从个体的参考范围进行比较。
5名患者未接受随访,23名患者的LDR值在预期范围内,8名患者的LDR值较低,表明依从性差。9名患有类固醇反应性疾病(峰值流量或肺量计参数改善>20%)的患者的LDR值均在预期范围内。
排除未接受随访(其依从性必然存疑)的患者,8名(26%)患者未完全依从类固醇试验。并非所有对为期两周的家庭类固醇试验无反应的患者都患有类固醇“无反应性”疾病。